Tilos Therapeutics, a quiet preclinical biotech developing treatments for cancer and autoimmune diseases, has become the latest startup to be acquired by pharmaceutical giant Merck & Co.
Merck (NYSE: MRK) announced Monday that it has agreed to pay upwards of $773 million in upfront and milestone payments for the purchase. A company spokesperson declined to disclose how much Merck paid upfront.
Privately held Tilos was founded in 2016 by Boehringer Ingelheim Venture Fund and Partners Healthcare’s…
Boston Biz Journal https://www.bizjournals.com/boston/news/2019/06/10/merck-snaps-up-preclinical-lexington-biotech-for.html?ana=RSS&s=article_search